Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 28 | 2021 | 42 | 8.550 |
Why?
|
| Antiviral Agents | 30 | 2021 | 71 | 7.130 |
Why?
|
| Hepatitis C | 19 | 2022 | 43 | 6.350 |
Why?
|
| Liver Diseases | 13 | 2022 | 33 | 5.090 |
Why?
|
| Hepacivirus | 23 | 2022 | 32 | 4.520 |
Why?
|
| Pregnancy Complications | 8 | 2022 | 44 | 3.800 |
Why?
|
| Liver Transplantation | 9 | 2023 | 86 | 3.750 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 5 | 2024 | 6 | 2.090 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2020 | 21 | 1.820 |
Why?
|
| Pregnancy | 13 | 2022 | 327 | 1.680 |
Why?
|
| Liver Cirrhosis | 12 | 2024 | 41 | 1.670 |
Why?
|
| Humans | 66 | 2024 | 25900 | 1.520 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2020 | 9 | 1.470 |
Why?
|
| Ribavirin | 8 | 2016 | 9 | 1.330 |
Why?
|
| Coinfection | 4 | 2023 | 20 | 1.260 |
Why?
|
| Sulfonamides | 7 | 2020 | 37 | 1.190 |
Why?
|
| Hepatitis B | 5 | 2019 | 10 | 1.170 |
Why?
|
| HIV Infections | 4 | 2021 | 475 | 1.120 |
Why?
|
| Female | 35 | 2024 | 14543 | 1.050 |
Why?
|
| United States | 18 | 2022 | 1935 | 1.040 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2024 | 5 | 1.020 |
Why?
|
| Liver Neoplasms | 3 | 2022 | 102 | 0.950 |
Why?
|
| Carbamates | 9 | 2020 | 9 | 0.920 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2022 | 25 | 0.910 |
Why?
|
| Quinoxalines | 5 | 2020 | 6 | 0.870 |
Why?
|
| Interferon-alpha | 4 | 2012 | 22 | 0.870 |
Why?
|
| Polyethylene Glycols | 4 | 2012 | 38 | 0.850 |
Why?
|
| Hepatitis D | 1 | 2023 | 1 | 0.840 |
Why?
|
| Treatment Outcome | 19 | 2021 | 3339 | 0.780 |
Why?
|
| Drug Therapy, Combination | 12 | 2021 | 158 | 0.770 |
Why?
|
| Gastroenterology | 3 | 2017 | 9 | 0.760 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2021 | 34 | 0.750 |
Why?
|
| Living Donors | 1 | 2021 | 17 | 0.720 |
Why?
|
| Prejudice | 1 | 2021 | 35 | 0.720 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 18 | 0.680 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 103 | 0.670 |
Why?
|
| Patient Selection | 1 | 2021 | 182 | 0.670 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 23 | 0.670 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 102 | 0.670 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 36 | 0.670 |
Why?
|
| Benzimidazoles | 3 | 2019 | 9 | 0.660 |
Why?
|
| Genotype | 10 | 2017 | 335 | 0.640 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2019 | 1 | 0.620 |
Why?
|
| Viral Load | 5 | 2016 | 75 | 0.610 |
Why?
|
| Algorithms | 2 | 2020 | 337 | 0.600 |
Why?
|
| Obesity | 1 | 2021 | 292 | 0.600 |
Why?
|
| Sofosbuvir | 6 | 2019 | 6 | 0.600 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 6 | 2019 | 6 | 0.600 |
Why?
|
| Adult | 19 | 2021 | 7517 | 0.580 |
Why?
|
| Fear | 1 | 2018 | 43 | 0.570 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2019 | 4 | 0.570 |
Why?
|
| Liver | 3 | 2022 | 150 | 0.560 |
Why?
|
| Cyclopropanes | 5 | 2020 | 12 | 0.520 |
Why?
|
| Drugs, Generic | 1 | 2016 | 1 | 0.520 |
Why?
|
| Antacids | 1 | 2016 | 1 | 0.510 |
Why?
|
| Middle Aged | 19 | 2021 | 8556 | 0.510 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 10 | 0.510 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 3 | 0.500 |
Why?
|
| Sustained Virologic Response | 6 | 2021 | 6 | 0.500 |
Why?
|
| Virology | 1 | 2015 | 1 | 0.490 |
Why?
|
| Length of Stay | 2 | 2016 | 307 | 0.450 |
Why?
|
| Young Adult | 9 | 2021 | 1929 | 0.450 |
Why?
|
| Patient Readmission | 1 | 2016 | 128 | 0.450 |
Why?
|
| Liver Function Tests | 3 | 2022 | 21 | 0.450 |
Why?
|
| Heart Failure | 1 | 2016 | 123 | 0.450 |
Why?
|
| Risk Factors | 6 | 2023 | 2173 | 0.430 |
Why?
|
| Prognosis | 5 | 2022 | 695 | 0.420 |
Why?
|
| Prevalence | 3 | 2023 | 431 | 0.420 |
Why?
|
| Patient Reported Outcome Measures | 6 | 2021 | 501 | 0.410 |
Why?
|
| Preventive Health Services | 1 | 2013 | 13 | 0.410 |
Why?
|
| Advisory Committees | 1 | 2013 | 19 | 0.410 |
Why?
|
| Male | 21 | 2021 | 14176 | 0.400 |
Why?
|
| Periodicals as Topic | 2 | 2023 | 35 | 0.400 |
Why?
|
| Health Policy | 1 | 2013 | 41 | 0.400 |
Why?
|
| Mass Screening | 4 | 2021 | 168 | 0.400 |
Why?
|
| Disease Management | 2 | 2016 | 91 | 0.390 |
Why?
|
| Retrospective Studies | 8 | 2024 | 3342 | 0.380 |
Why?
|
| Hepatitis C Antibodies | 2 | 2022 | 4 | 0.370 |
Why?
|
| Imidazoles | 4 | 2020 | 55 | 0.350 |
Why?
|
| Proline | 4 | 2019 | 10 | 0.350 |
Why?
|
| Lactams, Macrocyclic | 4 | 2019 | 6 | 0.350 |
Why?
|
| RNA, Viral | 4 | 2022 | 46 | 0.340 |
Why?
|
| Macrocyclic Compounds | 4 | 2019 | 4 | 0.330 |
Why?
|
| Pregnancy Outcome | 2 | 2021 | 20 | 0.330 |
Why?
|
| Drug Resistance, Viral | 4 | 2017 | 14 | 0.320 |
Why?
|
| Aged | 13 | 2020 | 8658 | 0.310 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 149 | 0.300 |
Why?
|
| Cost of Illness | 2 | 2023 | 47 | 0.290 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2008 | 2 | 0.290 |
Why?
|
| Motivation | 3 | 2023 | 89 | 0.280 |
Why?
|
| Fatty Liver | 2 | 2019 | 26 | 0.280 |
Why?
|
| Medication Adherence | 2 | 2019 | 38 | 0.270 |
Why?
|
| Recombinant Proteins | 4 | 2012 | 177 | 0.270 |
Why?
|
| Cohort Studies | 5 | 2021 | 1815 | 0.260 |
Why?
|
| Adolescent | 4 | 2020 | 2070 | 0.250 |
Why?
|
| Societies, Medical | 2 | 2017 | 118 | 0.250 |
Why?
|
| Benzofurans | 3 | 2020 | 5 | 0.240 |
Why?
|
| Graft Rejection | 2 | 2018 | 63 | 0.240 |
Why?
|
| Valine | 4 | 2019 | 5 | 0.230 |
Why?
|
| Incidence | 2 | 2020 | 720 | 0.220 |
Why?
|
| Cost-Benefit Analysis | 4 | 2021 | 123 | 0.220 |
Why?
|
| Pyrrolidines | 3 | 2018 | 11 | 0.210 |
Why?
|
| Hepatitis Delta Virus | 1 | 2023 | 1 | 0.210 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 1 | 0.210 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2023 | 4 | 0.210 |
Why?
|
| Amides | 2 | 2020 | 15 | 0.210 |
Why?
|
| Benzamides | 1 | 2023 | 12 | 0.200 |
Why?
|
| Chronic Disease | 3 | 2020 | 403 | 0.200 |
Why?
|
| Vaccination | 1 | 2023 | 29 | 0.200 |
Why?
|
| Ritonavir | 3 | 2019 | 3 | 0.200 |
Why?
|
| Uracil | 3 | 2019 | 4 | 0.200 |
Why?
|
| Risk Assessment | 2 | 2018 | 553 | 0.200 |
Why?
|
| Mastocytosis, Systemic | 1 | 2022 | 6 | 0.200 |
Why?
|
| RNA | 1 | 2022 | 41 | 0.190 |
Why?
|
| Fibrosis | 1 | 2022 | 30 | 0.190 |
Why?
|
| Selection Bias | 1 | 2021 | 9 | 0.190 |
Why?
|
| Graft Survival | 2 | 2019 | 89 | 0.180 |
Why?
|
| Fertility | 1 | 2021 | 13 | 0.180 |
Why?
|
| Aminoisobutyric Acids | 2 | 2018 | 2 | 0.180 |
Why?
|
| Leucine | 2 | 2018 | 10 | 0.180 |
Why?
|
| Critical Care | 1 | 2022 | 118 | 0.180 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 4633 | 0.180 |
Why?
|
| World Health Organization | 1 | 2020 | 9 | 0.170 |
Why?
|
| Tissue Donors | 1 | 2021 | 73 | 0.170 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 10 | 0.170 |
Why?
|
| Pandemics | 1 | 2022 | 221 | 0.170 |
Why?
|
| Recurrence | 2 | 2011 | 290 | 0.170 |
Why?
|
| Anilides | 2 | 2019 | 7 | 0.170 |
Why?
|
| 2-Naphthylamine | 2 | 2019 | 3 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2020 | 69 | 0.170 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 143 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2019 | 1686 | 0.160 |
Why?
|
| Consensus | 2 | 2021 | 91 | 0.160 |
Why?
|
| Forecasting | 1 | 2019 | 91 | 0.160 |
Why?
|
| Drug and Narcotic Control | 2 | 2016 | 3 | 0.160 |
Why?
|
| United States Food and Drug Administration | 2 | 2016 | 18 | 0.160 |
Why?
|
| Hyperemesis Gravidarum | 1 | 2019 | 1 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2019 | 55 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 251 | 0.150 |
Why?
|
| Transplant Recipients | 1 | 2018 | 20 | 0.150 |
Why?
|
| Internationality | 1 | 2018 | 20 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 314 | 0.140 |
Why?
|
| Infant, Newborn | 1 | 2019 | 553 | 0.140 |
Why?
|
| Drug Substitution | 1 | 2017 | 4 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 830 | 0.140 |
Why?
|
| Critical Pathways | 1 | 2017 | 18 | 0.140 |
Why?
|
| Psychometrics | 1 | 2018 | 203 | 0.130 |
Why?
|
| Patient Participation | 1 | 2017 | 44 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 1083 | 0.130 |
Why?
|
| Counterfeit Drugs | 1 | 2016 | 1 | 0.130 |
Why?
|
| Drug Approval | 1 | 2016 | 5 | 0.130 |
Why?
|
| Hospitalization | 2 | 2016 | 295 | 0.130 |
Why?
|
| Safety | 1 | 2016 | 35 | 0.130 |
Why?
|
| Canada | 1 | 2016 | 43 | 0.130 |
Why?
|
| Commerce | 1 | 2016 | 12 | 0.130 |
Why?
|
| Quality Control | 1 | 2016 | 26 | 0.130 |
Why?
|
| Ascites | 1 | 2016 | 2 | 0.130 |
Why?
|
| Paracentesis | 1 | 2016 | 3 | 0.130 |
Why?
|
| Interferons | 1 | 2016 | 8 | 0.130 |
Why?
|
| Fraud | 1 | 2016 | 21 | 0.130 |
Why?
|
| Eclampsia | 1 | 2016 | 1 | 0.130 |
Why?
|
| HELLP Syndrome | 1 | 2016 | 1 | 0.130 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 6 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 110 | 0.130 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2016 | 89 | 0.120 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 23 | 0.120 |
Why?
|
| Drug Interactions | 1 | 2015 | 34 | 0.120 |
Why?
|
| Directive Counseling | 1 | 2015 | 10 | 0.120 |
Why?
|
| Benchmarking | 1 | 2015 | 31 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2015 | 99 | 0.120 |
Why?
|
| Benzazepines | 1 | 2015 | 4 | 0.120 |
Why?
|
| Isoquinolines | 1 | 2015 | 11 | 0.120 |
Why?
|
| Indoles | 1 | 2015 | 31 | 0.120 |
Why?
|
| Time Factors | 2 | 2016 | 1376 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2017 | 149 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 264 | 0.110 |
Why?
|
| Phenotype | 1 | 2015 | 301 | 0.110 |
Why?
|
| Hospitalists | 1 | 2014 | 3 | 0.110 |
Why?
|
| Off-Label Use | 1 | 2014 | 6 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 56 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2014 | 69 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2016 | 206 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2014 | 96 | 0.100 |
Why?
|
| Viral Nonstructural Proteins | 3 | 2017 | 5 | 0.100 |
Why?
|
| Monitoring, Immunologic | 1 | 2012 | 1 | 0.100 |
Why?
|
| Drug Combinations | 3 | 2017 | 31 | 0.100 |
Why?
|
| Comorbidity | 3 | 2018 | 457 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 105 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2010 | 7 | 0.090 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2021 | 21 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 117 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2011 | 124 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2010 | 254 | 0.080 |
Why?
|
| Logistic Models | 1 | 2010 | 368 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 309 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 450 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 1708 | 0.080 |
Why?
|
| Fluorenes | 2 | 2019 | 2 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 196 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 847 | 0.060 |
Why?
|
| Hospital Costs | 2 | 2016 | 58 | 0.060 |
Why?
|
| Pyrroles | 1 | 2022 | 17 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 32 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2021 | 13 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2019 | 17 | 0.040 |
Why?
|
| Infection Control | 1 | 2021 | 170 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2019 | 34 | 0.040 |
Why?
|
| Insurance, Major Medical | 1 | 2018 | 1 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 19 | 0.040 |
Why?
|
| Registries | 1 | 2019 | 184 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 41 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2017 | 91 | 0.030 |
Why?
|
| Uridine Monophosphate | 1 | 2017 | 1 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 16 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 45 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 43 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2018 | 141 | 0.030 |
Why?
|
| Serine Proteases | 1 | 2016 | 7 | 0.030 |
Why?
|
| Career Choice | 1 | 2016 | 26 | 0.030 |
Why?
|
| Internal Medicine | 1 | 2016 | 30 | 0.030 |
Why?
|
| Pain Management | 1 | 2018 | 142 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 31 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 28 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 421 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 619 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 113 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2016 | 127 | 0.030 |
Why?
|
| Curriculum | 1 | 2016 | 136 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 328 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2016 | 201 | 0.030 |
Why?
|
| Drug Industry | 1 | 2014 | 6 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 52 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 42 | 0.030 |
Why?
|
| Inpatients | 1 | 2014 | 121 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 34 | 0.020 |
Why?
|
| Immunoassay | 1 | 2012 | 36 | 0.020 |
Why?
|
| Probability | 1 | 2012 | 84 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 110 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 893 | 0.020 |
Why?
|